Quantbot Technologies LP Lowers Stock Holdings in IQVIA Holdings Inc. $IQV

Key Points

• Quantbot Technologies LP reduced its stake in IQVIA Holdings Inc. by 49.3% in Q1, now holding 15,758 shares valued at $2.78 million.
• IQVIA reported Q2 earnings of $2.81 per share, exceeding analyst expectations, with revenue of $4.02 billion, up 5.3% year-over-year.
• Analysts have a consensus rating of "Moderate Buy" on IQVIA shares with an average target price of $228.62.

Quantbot Technologies LP lowered its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 49.3% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 15,758 shares of the medical research company's stock after selling 15,304 shares during the period. Quantbot Technologies LP's holdings in IQVIA were worth $2,778,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the stock. JPMorgan Chase & Co. increased its stake in IQVIA by 45.7% in the 1st quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company's stock valued at $448,686,000 after buying an additional 798,534 shares during the period. Northern Trust Corp increased its stake in shares of IQVIA by 16.2% during the fourth quarter. Northern Trust Corp now owns 1,791,229 shares of the medical research company's stock worth $351,994,000 after acquiring an additional 250,141 shares during the period. American Century Companies Inc. raised its holdings in IQVIA by 26.8% during the first quarter. American Century Companies Inc. now owns 1,438,995 shares of the medical research company's stock worth $253,695,000 after purchasing an additional 304,258 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in IQVIA by 2.9% in the first quarter. Dimensional Fund Advisors LP now owns 1,428,561 shares of the medical research company's stock valued at $251,852,000 after purchasing an additional 40,699 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in IQVIA by 13.6% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,393,140 shares of the medical research company's stock valued at $273,766,000 after purchasing an additional 167,057 shares during the period. 89.62% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on IQV shares. William Blair reissued an "outperform" rating on shares of IQVIA in a research note on Wednesday, July 23rd. Truist Financial increased their price objective on IQVIA from $209.00 to $235.00 and gave the stock a "buy" rating in a research report on Wednesday, July 23rd. JPMorgan Chase & Co. decreased their target price on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a research report on Monday, May 19th. Robert W. Baird increased their price target on shares of IQVIA from $159.00 to $196.00 and gave the company a "neutral" rating in a report on Wednesday, July 23rd. Finally, Redburn Partners set a $188.00 price objective on shares of IQVIA in a research note on Friday, May 23rd. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $228.62.

Insider Buying and Selling

In related news, insider Keriann Cherofsky sold 549 shares of the stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the sale, the insider owned 2,910 shares of the company's stock, valued at $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Eric Sherbet sold 5,800 shares of the business's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the transaction, the insider directly owned 27,178 shares of the company's stock, valued at $5,165,178.90. The trade was a 17.59% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by corporate insiders.

IQVIA Price Performance

Shares of NYSE:IQV traded up $5.5970 during midday trading on Friday, hitting $190.9870. 1,619,418 shares of the stock were exchanged, compared to its average volume of 1,441,272. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $252.88. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.45. The company has a 50 day moving average price of $173.70 and a 200-day moving average price of $168.26. The stock has a market cap of $32.47 billion, a P/E ratio of 27.64, a PEG ratio of 2.10 and a beta of 1.30.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating analysts' consensus estimates of $2.77 by $0.04. The firm had revenue of $4.02 billion for the quarter, compared to analysts' expectations of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The firm's revenue was up 5.3% on a year-over-year basis. During the same period in the prior year, the company earned $2.64 EPS. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.